Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Cell Death01:30

Overview of Cell Death

9.6K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
9.6K
Autophagic Cell Death01:18

Autophagic Cell Death

4.4K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.4K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

425
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
425
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

155
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
155
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

250
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
250
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

1.1K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robot-Related Workers' Compensation Claims in Ohio, 2001-2020.

American journal of industrial medicine·2026
Same author

Correction: Opioid prescriptions among the World Trade Center Health Program population.

BMC health services research·2024
Same author

Opioid prescriptions among the World Trade Center Health Program population.

BMC health services research·2023
Same author

Occupational injuries and illnesses among law enforcement officers, 2001-2019: Findings from the Ohio Bureau of Workers' Compensation.

American journal of industrial medicine·2023
Same author

2022 National Occupational Injury Research Symposium (NOIRS): Preventing workplace injuries in a changing world.

Journal of safety research·2023
Same author

Construction industry workers' compensation injury claims due to slips, trips, and falls - Ohio, 2010-2017.

Journal of safety research·2023

Related Experiment Video

Updated: Jan 26, 2026

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

889

Drug overdose deaths at work, 2011-2016.

Hope M Tiesman1, Srinivas Konda2, Lauren Cimineri3

  • 1Division of Safety Research, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC/NIOSH), Morgantown, West Virginia, USA htiesman@cdc.gov.

Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention
|April 12, 2019
PubMed
Summary

Workplace drug overdose deaths increased 24% annually from 2011-2016, impacting transportation and mining industries. Heroin was the most frequent drug involved in these fatalities.

Keywords:
overdosessurveillanceworkplace

More Related Videos

Author Spotlight: A Streamlined Approach to Studying Cell Death Initiation in Hypersensitive Response
06:06

Author Spotlight: A Streamlined Approach to Studying Cell Death Initiation in Hypersensitive Response

Published on: November 10, 2023

2.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

Related Experiment Videos

Last Updated: Jan 26, 2026

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

889
Author Spotlight: A Streamlined Approach to Studying Cell Death Initiation in Hypersensitive Response
06:06

Author Spotlight: A Streamlined Approach to Studying Cell Death Initiation in Hypersensitive Response

Published on: November 10, 2023

2.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

Area of Science:

  • Occupational Health
  • Public Health
  • Epidemiology

Background:

  • Drug overdose fatalities have significantly increased nationwide.
  • The impact of this epidemic on US workplaces remains largely undescribed.

Purpose of the Study:

  • To describe the trends and characteristics of drug overdose deaths in US workplaces between 2011 and 2016.
  • To identify industries and demographic groups most affected by workplace overdose fatalities.

Main Methods:

  • Data on workplace drug overdose deaths were obtained from the Census of Fatal Occupational Injuries.
  • Fatality rates were calculated using Current Population Survey data for full-time equivalents (FTEs).
  • Negative binomial regression analysis was used to assess trends.

Main Results:

  • A total of 760 workplace drug overdoses occurred between 2011 and 2016, with a fatality rate of 0.9 per 1,000,000 FTEs.
  • Workplace overdose fatality rates increased by 24% annually.
  • The highest rates were observed in the transportation (3.0 per 1,000,000 FTEs) and mining (2.6 per 1,000,000 FTEs) industries.
  • Seventeen percent of workplace overdose deaths involved heroin.
  • One-third of fatalities occurred in small businesses with fewer than 10 employees.

Conclusions:

  • While workplace overdose deaths were relatively low, they demonstrated a considerable increase over the study period.
  • Workplaces are significantly impacted by the national opioid overdose epidemic.
  • Targeted prevention strategies may be needed for high-risk industries and small businesses.